Log in

ASX:PNVPolynovo Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/12/2020)
Today's Range
Now: A$2.49
50-Day Range
MA: A$2.19
52-Week Range
Now: A$2.49
Volume3.38 million shs
Average VolumeN/A
Market Capitalization$1.65 billion
P/E RatioN/A
Dividend YieldN/A
Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in Australia. The company focuses on the development and commercialization of medical devices using its NovoSorb technology in the treatment of burns, surgical wounds, and negative pressure wound therapy. It offers BTM (biodegradable temporising matrix), a wound dressing intended for treatment of full-thickness wounds and burns. In addition, Polynovo Limited licensed its NovoSorb to Smith & Nephew for orthopaedic applications. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited is based in Port Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 8681 4050



Sales & Book Value

Annual Sales$18.56 million
Cash FlowA$0.01 per share
Book ValueA$0.04 per share



Market Cap$1.65 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive PNV News and Ratings via Email

Sign-up to receive the latest news and ratings for PNV and its competitors with MarketBeat's FREE daily newsletter.

Polynovo (ASX:PNV) Frequently Asked Questions

How has Polynovo's stock been impacted by COVID-19 (Coronavirus)?

Polynovo's stock was trading at A$1.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PNV stock has increased by 31.1% and is now trading at A$2.49. View which stocks have been most impacted by Coronavirus.

Has Polynovo been receiving favorable news coverage?

Headlines about PNV stock have trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Polynovo earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutPolynovo.

Who are some of Polynovo's key competitors?

What other stocks do shareholders of Polynovo own?

Who are Polynovo's key executives?

Polynovo's management team includes the following people:
  • Mr. Paul Brennan, Chief Exec. Officer
  • Mr. Greg Lewis M.A.I.C.D., M.B.A., Chief Operating Officer
  • Mr. Jan-Marcel Gielen, CFO & Company Sec.
  • Dr. Tim Moore, Principal Scientist
  • Mr. David Smith, Manufacturing Mang.

What is Polynovo's stock symbol?

Polynovo trades on the ASX under the ticker symbol "PNV."

What is Polynovo's stock price today?

One share of PNV stock can currently be purchased for approximately A$2.49.

How big of a company is Polynovo?

Polynovo has a market capitalization of $1.65 billion and generates $18.56 million in revenue each year. Polynovo employs 41 workers across the globe.

What is Polynovo's official website?

The official website for Polynovo is www.polynovo.com.au.

How can I contact Polynovo?

The company can be reached via phone at 61 3 8681 4050.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.